158 related articles for article (PubMed ID: 23848522)
1. Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo.
Wang X; Wang L; Wan M; Wu X; Yu Y; Wang L
Nucleic Acid Ther; 2013 Aug; 23(4):253-63. PubMed ID: 23848522
[TBL] [Abstract][Full Text] [Related]
2. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
3. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z; Guo K; Schluesener HJ
J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
[TBL] [Abstract][Full Text] [Related]
4. The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes.
Roberts TL; Dunn JA; Sweet MJ; Hume DA; Stacey KJ
Mol Immunol; 2011 Apr; 48(8):1027-34. PubMed ID: 21324527
[TBL] [Abstract][Full Text] [Related]
5. Phosphorothioate oligodeoxyribonucleotides induce in vitro proliferation of chicken B-cells.
Wattrang E
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):218-28. PubMed ID: 19447503
[TBL] [Abstract][Full Text] [Related]
6. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis.
Shen W; Waldschmidt M; Zhao X; Ratliff T; Krieg AM
Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):155-64. PubMed ID: 12162698
[TBL] [Abstract][Full Text] [Related]
7. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
Ballas ZK; Rasmussen WL; Krieg AM
J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
[TBL] [Abstract][Full Text] [Related]
8. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory CpG-oligodeoxynucleotides induce a factor that inhibits macrophage adhesion.
Macfarlane DE; Manzel L
J Lab Clin Med; 1999 Nov; 134(5):501-9. PubMed ID: 10560944
[TBL] [Abstract][Full Text] [Related]
10. The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.
Bjersing JL; Eriksson K; Tarkowski A; Collins LV
Inflammation; 2004 Feb; 28(1):39-51. PubMed ID: 15072229
[TBL] [Abstract][Full Text] [Related]
11. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
[TBL] [Abstract][Full Text] [Related]
12. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Qu X; Felder MA; Perez Horta Z; Sondel PM; Rakhmilevich AL
Int Immunopharmacol; 2013 Dec; 17(4):1141-7. PubMed ID: 24201083
[TBL] [Abstract][Full Text] [Related]
14. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma.
Yudoh K; Matsuno H; Kimura T
J Lab Clin Med; 1999 Feb; 133(2):120-8. PubMed ID: 9989763
[TBL] [Abstract][Full Text] [Related]
15. Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade.
Zhang Y; Lin A; Sui Q; Zhang C; Tian Z; Zhang J
Cancer Lett; 2014 Dec; 355(1):76-84. PubMed ID: 25224571
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
17. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
[TBL] [Abstract][Full Text] [Related]
19. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
20. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells.
Kunikata N; Sano K; Honda M; Ishii K; Matsunaga J; Okuyama R; Takahashi K; Watanabe H; Tamura G; Tagami H; Terui T
J Invest Dermatol; 2004 Aug; 123(2):395-402. PubMed ID: 15245441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]